Baratchian, MehdiMcManus, JeffreyBerk, MikeNakamura, FumihikoErzurum, SerpilMukhopadhyay, SanjayDrazba, JudyPeterson, JohnGaston, BenSharifi, Nima2020-07-162020-07-162020-03-21Baratchian, M., McManus, J., Berk, M., Nakamura, F., Erzurum, S., Mukhopadhyay, S., Drazba, J., Peterson, J., Gaston, B., & Sharifi, N. (2020). No evidence that androgen regulation of pulmonary TMPRSS2 explains sex-discordant COVID-19 outcomes. BioRxiv, 2020.04.21.051201. https://doi.org/10.1101/2020.04.21.051201https://hdl.handle.net/1805/23242<h3>Abstract</h3> <p>The recent emergence of SARS-CoV-2 and the subsequent COVID-19 pandemic have posed a public health crisis. Higher morbidity and mortality of men with COVID-19 may be explained by androgen-driven mechanisms. One such proposed mechanism is androgen regulation of pulmonary TMPRSS2, the host co-receptor for SARS-CoV-2. We find no evidence for increased <i>TMPRSS2</i> mRNA expression in the lungs of males compared to females in humans or mice. Furthermore, in male mice, treatment with the androgen receptor antagonist enzalutamide does not decrease pulmonary TMPRSS2 expression. Nevertheless, regardless of sex, smoking significantly increases the expression of <i>TMPRSS2</i>, which reverts back to never-smoker levels in former smokers. Finally, we show that in mouse models, despite equivalent AR transcript levels, males express markedly higher amounts of AR protein. If a similar sex-specific regulation of AR protein occurs in human lung, androgens could play important roles in clinical outcome of COVID-19 through mechanisms other than TMPRSS2 regulation.</p>en-USPublisher PolicyCOVID-19Pulmonary TMPRSS2Androgen RegulationArticle